Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - Neurocrine's growth strategy is centered around three key pillars: INGREZZA, CRENESSITY, and a robust R&D pipeline [3] Group 1: Product Overview - INGREZZA is Neurocrine's primary product for treating tardive dyskinesia, approved in 2017, and later for chorea associated with Huntington's Disease [3] - CRENESSITY, a recently approved medication for congenital adrenal hyperplasia, was launched in December 2024, marking its first full year in the market [3] Group 2: Company Positioning - The company emphasizes its commitment to maintaining a deep and sustainable research and development pipeline to support future growth [3]